Company intelligence / Profile preview
SoVarGen
Daejeon, South Koreasovargen.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
SoVarGen has multiple programs in development with their lead candidate SVG-103 in Phase 2 for Tuberous Sclerosis. The company has several other candidates in preclinical and discovery stages targeting various neurological conditions and brain cancers[2].
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- OligonucleotideBiological productsASO (Antisense Oligonucleotide)RNA therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Kazia Therapeutics (licensed paxalisib to SoVarGen for intractable seizures in rare central nervous system diseases)[3]
Beyond the preview
Go deeper on SoVarGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SoVarGen.